Europe Underactive Bladder Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143202
- Pages: 225
-
Format:
Short Description
Europe Underactive Bladder Market, By Treatment (Pharmacotherapy, Surgical Methods, Urethral Assist Device, and Stem Cell and Gene Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Clinics, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, and Rest of Europe) Industry Trends and Forecast to 2029
Market Definition
Underactive Bladder (UAB) is a clinical condition in which urination disorder is developed as a result of reduction in the contraction of detrusor muscle (a muscle of the bladder) during urination. It is characterized by the feeling of having to urinate immediately, and thus, this condition is different from an Overactive Bladder (OAB). The present invention provides a pharmaceutical composition useful for the prevention or treatment of UAB which has an effect of improving the urinary flow rate, an effect of improving the overdistension of the bladder (an effect of reducing bladder capacity), and is, therefore, useful for the prevention or treatment of UAB.
Moreover, it is a disease state which is different from OAB characterized by urinary urgency which has been attracting attention in recent years. Causes of UAB include autonomic neuropathy such as diabetes and alcoholism, pelvic surgery such as radical hysterectomy and radical rectal cancer, spinal cord diseases such as spina bifida, and disc herniation is also known. The market is driven by the factors such as the rising incidences of prevalence of neurogenic bladder infections, increasing research funding, development of novel therapies for UAB, and pipeline products enhancing its demand as well as rising investment in R&D leads to the market growth. Additionally, the surge in healthcare expenditure and increase in the prevalence of bladder disorders positively affect the market. However, the high cost of treatment restricts patients to accommodate high-quality and effective solutions.
Market Segmentation
Europe underactive bladder market is categorized based on treatment, route of administration, end user, and distribution channel.
Based on treatment, the market is segmented into pharmacotherapy, surgical methods, urethral assist device, and stem cell and gene therapies
Based on route of administration, the market is segmented into oral, parenteral, and others
Based on end user, the market is segmented into hospitals, clinics, academic and research institutes, and others
Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others
Market Players
The key market players operating in the Europe underactive bladder market are listed below:
Astellas Pharma Inc.
Aurobindo Pharma.
Boehringer Ingelheim International GmbH
Macleods Pharmaceuticals Ltd.
Orion Corporation
ONO PHARMACEUTICAL CO., LTD.
Novartis AG
Pfizer Inc.
Cipla Inc.
Dr. Reddys Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Almirall, S.A
Glenwood
Alkem Labs.
TABLE OF CONTENTS
1 INTRODUCTION 46
1.1 OBJECTIVES OF THE STUDY 46
1.2 MARKET DEFINITION 46
1.3 OVERVIEW OF THE EUROPE UNDERACTIVE BLADDER MARKET 46
1.4 LIMITATIONS 48
1.5 MARKETS COVERED 48
2 MARKET SEGMENTATION 51
2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 CURRENCY AND PRICING 53
2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
2.6 MULTIVARIATE MODELLING 57
2.7 PRODUCT SEGMENT LIFELINE CURVE 57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
2.9 DBMR MARKET POSITION GRID 59
2.10 MARKET APPLICATION COVERAGE GRID 60
2.11 VENDOR SHARE ANALYSIS 61
2.12 SECONDARY SOURCES 62
2.13 ASSUMPTIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 66
4.1 PESTEL ANALYSIS 67
4.2 PORTERS FIVE FORCES 68
4.3 EPIDEMIOLOGY 69
4.4 THE IMPORTANCE OF UNDERSTANDING PATENTS- 71
4.4.1 DOXAZOSIN 71
4.4.2 BETHANECHOL CHLORIDE 78
4.4.3 TAMSULOSIN HYDROCHLORIDE 86
4.5 CLINICAL TRIALS FOR UNDERACTIVE BLADDER 88
4.5.1 EU CLINICAL TRIALS REGISTER- 97
4.6 MERGER & ACQUISITION IN HEALTHCARE INDUSTRY 100
4.7 M&A DEALS IN 2021 BY TARGET COMPANY TERRITORY: 102
4.8 CROSS-BORDER DEALS: 103
4.9 OUTLOOK FOR 2022: 103
4.10 PATIENT ENROLMENT STRATEGIES 104
4.11 FACTORS AFFECTING PATIENT RECRUITMENT: 105
4.12 CHALLENGES: 105
4.13 PATIENT FUNNEL ANALYSIS: 105
4.14 RECOMMENDATIONS 106
4.14.1 USE OF TECHNOLOGY: 106
4.14.2 PARTICIPANT CHARACTERISTICS: 106
4.14.3 RECRUITER CHARACTERISTICS: 106
4.14.4 SYSTEMS & PROCEDURES: 106
4.14.5 LOCATION: 107
4.14.6 NATURE OF RESEARCH: 107
4.15 CONCLUSION: 107
4.16 UNDERACTIVE BLADDER PATIENT FLOW DIAGRAM 108
4.17 WHAT CAUSES UNDERACTIVE BLADDER 108
4.17.1 CAUSES OF UNDERACTIVE BLADDER INCLUDE 108
4.17.2 TESTS TO EVALUATE UNDERACTIVE BLADDER 108
4.18 UNDERACTIVE BLADDER INVESTIGATIONAL PRODUCTS- 109
5 EUROPE UNDERACTIVE BLADDER MARKET: REGULATIONS 112
6 MARKET OVERVIEW 114
6.1 DRIVERS 116
6.1.1 INCREASING PREVALENCE OF NEUROGENIC DISORDER 116
6.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF UNDERACTIVE BLADDER TREATMENT 116
6.1.3 FAVOURABLE REIMBURSEMENT SCENARIO 117
6.1.4 RISING HEALTHCARE EXPENDITURE 117
6.2 RESTRAINTS 118
6.2.1 HIGH COST OF RESEARCH AND DEVELOPMENT 118
6.2.2 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL 118
6.3 OPPORTUNITIES 119
6.3.1 RISING UROLOGIC COMPLICATIONS OF DIABETES 119
6.3.2 PRESENCE OF NOVEL PIPELINE DRUGS 120
6.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 120
6.4 CHALLENGES 120
6.4.1 LACK OF PROPER TREATMENT 120
6.4.2 RISK INVOLVED DURING TREATMENT OF UNDERACTIVE BLADDER 121
7 EUROPE UNDERACTIVE BLADDER MARKET, BY TYPE 122
7.1 OVERVIEW 123
7.2 PHARMACOTHERAPY 126
7.2.1 ALPHA-BLOCKERS 127
7.2.2 MUSCARINIC AGONISTS 127
7.2.3 CHOLINESTERASE INHIBITOR 127
7.2.3.1 BY DRUGS 127
7.2.3.1.1 TAMSULOSIN 128
7.2.3.1.2 DOXAZOSIN 128
7.2.3.1.3 DISTIGMINE 128
7.2.3.1.4 BETHANECHOL 128
7.2.3.1.5 OTHERS 128
7.2.4 BY PRODUCT TYPES 128
7.2.4.1 GENERICS 129
7.2.4.2 BRANDED 129
7.2.4.2.1 FLOMAX 129
7.2.4.2.2 ALFADIL 129
7.2.4.2.3 GRAVITOR 129
7.2.4.2.4 URIVOID 129
7.2.4.2.5 OTHERS 129
7.3 SURGICAL METHODS 130
7.3.1 SURGICAL NERVE STIMULATION 131
7.3.2 REDUCTION CYSTOPLASTY 131
7.3.3 SURGERIES FOR BLADDER OBSTRUCTION 131
7.3.4 INJECTION INTO EXTERNAL SPHINCTER 131
7.3.5 OTHERS 131
7.4 URETHRAL ASSIS DEVICE 132
7.4.1 INFLOW INTRAURETHRAL VALVE PUMP 133
7.5 STEM CELL AND GENE THERAPIES 134
7.5.1 NERVE GROWTH FACTOR 136
7.5.2 GLIAL-CELL DERIVE NEUTOPHIC FACTORGLIAL 136
7.5.3 NEUTOPHIN-3 DERIVES FROM GLIALL CELLS 136
8 EUROPE UNDERACTIVE BLADDER MARKET,BY ROUTE OF ADMINISTRATION 137
8.1 OVERVIEW 138
8.2 PARENTERAL 141
8.3 ORAL 141
8.4 OTHERS 143
9 EUROPE UNDERACTIVE BLADDER MARKET , BY END USER 144
9.1 OVERVIEW 145
9.2 HOSPITALS 148
9.3 CLINICS 148
9.4 ACADEMIC AND RESEARCH 150
9.5 OTHERS 150
10 EUROPE UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL 152
10.1 OVERVIEW 153
10.2 HOSPITAL PHARMACY 156
10.3 RETAIL PHARMACY 156
10.4 OTHERS 158
11 EUROPE UNDERACTIVE BLADDER MARKET, BY REGION 159
11.1 EUROPE 160
11.1.1 GERMANY 169
11.1.2 FRANCE 173
11.1.3 U.K. 177
11.1.4 ITALY 181
11.1.5 RUSSIA 186
11.1.6 SPAIN 190
11.1.7 TURKEY 194
11.1.8 NETHERLANDS 198
11.1.9 SWITZERLAND 203
11.1.10 POLAND 208
11.1.11 AUSTRIA 212
11.1.12 HUNGARY 216
11.1.13 NORWAY 220
11.1.14 IRELAND 224
11.1.15 LITHUANIA 228
11.1.16 REST OF EUROPE 233
12 EUROPE UNDERACTIVE BLADDER MARKET: COMPANY LANDSCAPE 234
12.1 COMPANY SHARE ANALYSIS: EUROPE 234
13 SWOT ANALYSIS 235
14 COMPANY PROFILES 236
14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 236
14.1.1 COMPANY SNAPSHOT 236
14.1.2 COMPANY SHARE ANALYSIS 236
14.1.3 PRODUCT PORTFOLIO 237
14.1.4 RECENT DEVELOPMENT 237
14.2 PFIZER INC. 238
14.2.1 COMPANY SNAPSHOT 238
14.2.2 REVENUE ANALYSIS 238
14.2.3 COMPANY SHARE ANALYSIS 239
14.2.4 PRODUCT PORTFOLIO 239
14.2.5 RECENT DEVELOPMENT 239
14.3 SUN PHARMACEUTICAL INDUSTRIES LTD. 240
14.3.1 COMPANY SNAPSHOT 240
14.3.2 REVENUE ANALYSIS 240
14.3.3 COMPANY SHARE ANALYSIS 241
14.3.4 PRODUCT PORTFOLIO 241
14.3.5 RECENT DEVELOPMENT 241
14.4 TEVA PHARMACEUTICAL INDUSTRIES LTD 242
14.4.1 COMPANY SNAPSHOT 242
14.4.2 REVENUE ANALYSIS 242
14.4.3 COMPANY SHARE ANALYSIS 243
14.4.4 PRODUCT PORTFOLIO 243
14.4.5 RECENT DEVELOPMENT 243
14.5 NOVARTIS AG 244
14.5.1 COMPANY SNAPSHOT 244
14.5.2 REVENUE ANALYSIS 244
14.5.3 COMPANY SHARE ANALYSIS 245
14.5.4 PRODUCT PORTFOLIO 245
14.5.5 RECENT DEVELOPMENT 245
14.6 DR. REDDYS LABORATORIES LTD. 246
14.6.1 COMPANY SNAPSHOT 246
14.6.2 REVENUE ANALYSIS 246
14.6.3 PRODUCT PORTFOLIO 247
14.6.4 RECENT DEVELOPMENT 247
14.7 ASTELLAS PHARMA INC. 248
14.7.1 COMPANY SNAPSHOT 248
14.7.2 REVENUE ANALYSIS 248
14.7.3 PRODUCT PORTFOLIO 249
14.7.4 RECENT DEVELOPMENT 249
14.8 ORION CORPORATION. 250
14.8.1 COMPANY SNAPSHOT 250
14.8.2 REVENUE ANALYSIS 250
14.8.3 PRODUCT PORTFOLIO 251
14.8.4 RECENT DEVELOPMENT 251
14.9 ALKEM LABS. 252
14.9.1 COMPANY SNAPSHOT 252
14.9.2 REVENUE ANALYSIS 252
14.9.3 PRODUCT PORTFOLIO 253
14.9.4 RECENT DEVELOPMENT 253
14.10 ALMIRALL, S.A 254
14.10.1 COMPANY SNAPSHOT 254
14.10.2 REVENUE ANALYSIS 254
14.10.3 PRODUCT PORTFOLIO 255
14.10.4 RECENT DEVELOPMENT 255
14.11 AUROBINDO PHARMA. 256
14.11.1 COMPANY SNAPSHOT 256
14.11.2 REVENUE ANALYSIS 256
14.11.3 PRODUCT PORTFOLIO 257
14.11.4 RECENT DEVELOPMENT 257
14.12 CIPLA INC. 258
14.12.1 COMPANY SNAPSHOT 258
14.12.2 REVENUE ANALYSIS 258
14.12.3 PRODUCT PORTFOLIO 259
14.12.4 RECENT DEVELOPMENT 259
14.13 GLENWOOD 260
14.13.1 COMPANY SNAPSHOT 260
14.13.2 PRODUCT PORTFOLIO 260
14.13.3 RECENT DEVELOPMENT 260
14.14 MACLEODS PHARMACEUTICALS LTD. 261
14.14.1 COMPANY SNAPSHOT 261
14.14.2 REVENUE ANALYSIS 261
14.14.3 PRODUCT PORTFOLIO 262
14.14.4 RECENT DEVELOPMENT 262
14.15 ONO PHARMACEUTICAL CO., LTD. 263
14.15.1 COMPANY SNAPSHOT 263
14.15.2 REVENUE ANALYSIS 263
14.15.3 PRODUCT PORTFOLIO 264
14.15.4 RECENT DEVELOPMENT 264
14.16 VESIFLO, INC. 265
14.16.1 COMPANY SNAPSHOT 265
14.16.2 PRODUCT PORTFOLIO 265
14.16.3 RECENT DEVELOPMENTS 265
15 QUESTIONNAIRE 266
16 RELATED REPORTS 268
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
